UPDATE: BMO Capital Raises PT on AbbVie Following 1Q13 Earnings Call Benzinga In the meantime, the pipeline is advancing well, with a number of meaningful data readouts expected later this year (e.g., ABT-199 at ASCO, initial Hep-C phase-3 at AASLD in November) and in 2014 (e.g., Daclizumab phase-3).” AbbVie closed on Friday at ... Goldman Sachs Raises PT on Abbvie (ABBV) to $52 |
